What the FDA labels say about taking them together
Escitalopram and sumatriptan
Escitalopram's FDA label of October 1, 2023 names sumatriptan in its drug interactions section; sumatriptan's label does not name escitalopram itself but warns about its class (serotonin reuptake inhibitors).
Check it at the source: the escitalopram FDA label on DailyMed (effective October 1, 2023, Allergan, Inc.); the sumatriptan FDA label on DailyMed (effective May 12, 2026, Aurobindo Pharma Limited).
What does the escitalopram label say about sumatriptan?
Escitalopram label, drug interactionsSumatriptan Clinical Impact: There have been postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of an SSRI and sumatriptan. Intervention: If concomitant treatment with sumatriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised [see Warning and Precautions ()].
Escitalopram label (Almatica Pharma LLC, August 31, 2025), drug interactionsPrevention or Management; If concomitant use of Escitalopram Capsules and sumatriptan is clinically warranted, appropriate observation of the patient is advised [see Warnings and Precautions ()].
Source: FDA drug label (Escitalopram, NDA219130), Almatica Pharma LLC, effective August 31, 2025 (SPL set c0401570-a3b0-bef2-7365-c23dc952b8b6), via openFDA
Source: FDA drug label (Lexapro), NDA021323 (Abbvie), as published by Allergan, Inc., effective October 1, 2023 (SPL set 13bb8267-1cab-43e5-acae-55a4d957630a), via openFDA; the full label on DailyMed
What does the sumatriptan label say about escitalopram?
Sumatriptan's label does not name escitalopram itself; it warns about its class (serotonin reuptake inhibitors):
Sumatriptan label, drug interactionsInhibitors and Serotonin Syndrome Cases of serotonin syndrome have been reported during co-administration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.7) ].
Sumatriptan label, warnings and precautionsSerotonin syndrome may occur with sumatriptan tablets, particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Drug Interactions (7.4) ].
Source: FDA drug label (Sumatriptan), Aurobindo Pharma Limited, effective May 12, 2026 (SPL set b2503fff-c978-4efa-b1b4-d7740b6b26f2), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Escitalopram | Sumatriptan | |
|---|---|---|
| Labeled for | Depression, Anxiety | Migraine |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.0632 per tablet 20 mg tablet | $0.302 per tablet 50 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once